MedTrace Logo

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

NCT03229200 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 297

Last updated 2025-10-30

No results posted yet for this study

Summary

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.

Conditions

  • Lymphoma, B-Cell
  • Lymphoma, Non-Hodgkin
  • Leukemia, B-cell
  • Graft Vs Host Disease
  • Solid Tumor

Interventions

DRUG

Ibrutinib

Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.

Sponsors & Collaborators

  • Janssen Biotech, Inc., including Johnson & Johnson

    collaborator UNKNOWN

  • Pharmacyclics Switzerland GmbH

    lead INDUSTRY

Principal Investigators

  • Kevin Wu · AbbVie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-22
Primary Completion
2027-05-10
Completion
2027-05-10
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Czechia
  • France
  • Hungary
  • Italy
  • New Zealand
  • Poland
  • Russia
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03229200 on ClinicalTrials.gov